ArticlePharmaceutical research2012
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.
Article in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.Clinical pharmacokinetics · 2012Pooled it
- Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.British journal of haematology · 2021Trial
- Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.CPT: pharmacometrics & systems pharmacology · 2017Trial
- Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population.Journal of clinical pharmacology · 2026Observational
- All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology.Clinical pharmacokinetics · 2025Review
- Population Pharmacokinetic Modeling Analysis of ASC10, a Novel Antiviral Agent Targeted COVID-19, in Chinese Healthy Subjects.Drug design, development and therapy · 2025Article
- Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children.CPT: pharmacometrics & systems pharmacology · 2024Article
- A General Biphasic Bodyweight Model for Scaling Basal Metabolic Rate, Glomerular Filtration Rate, and Drug Clearance from Birth to Adulthood.The AAPS journal · 2022Article
- Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support.Frontiers in pharmacology · 2021Article
- Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.Clinical pharmacology and therapeutics · 2021Article
- Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.Clinical pharmacokinetics · 2019Article
- Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics.British journal of clinical pharmacology · 2019Article
- Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.European journal of clinical pharmacology · 2019Article
- The use of PBPK modeling across the pediatric age range using propofol as a case.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.Antimicrobial agents and chemotherapy · 2018Article
- Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".Clinical pharmacokinetics · 2018Article
- Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.Clinical pharmacokinetics · 2018Observational
- Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.British journal of clinical pharmacology · 2017Article
- Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.Clinical pharmacokinetics · 2017Article
- Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials.Pharmaceutical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore different allometric equations for scaling clearance across the human life-span using propofol as a model drug.
methodsData from seven previously published propofol studies ((pre)term neonates, infants, toddlers, children, adolescents and adults) were analysed using NONMEM VI. To scale clearance, a bodyweight-based exponential equation with four different structures for the exponent was used: (I) 3/4 allometric scaling model; (II) mixture model; (III) bodyweight-cut-point separated model; (IV) bodyweight-dependent exponent model.
resultsModel I adequately described clearance in adults and older children, but overestimated clearance of neonates and underestimated clearance of infants. Use of two different exponents in Model II and Model III showed significantly improved performance, but yielded ambiguities on the boundaries of the two subpopulations. This discontinuity was overcome in Model IV, in which the exponent changed sigmoidally from 1.35 at a hypothetical bodyweight of 0 kg to a value of 0.56 from 10 kg onwards, thereby describing clearance of all individuals best.
conclusionsA model was developed for scaling clearance over the entire human life-span with a single continuous equation, in which the exponent of the bodyweight-based exponential equation varied with bodyweight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.